de Perrot Marc, Chaparro Cecilia, McRae Karen, Waddell Thomas K, Hadjiliadis Denis, Singer Lianne G, Pierre Andrew F, Hutcheon Michael, Keshavjee Shaf
Toronto Lung Transplant Program, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
J Thorac Cardiovasc Surg. 2004 May;127(5):1493-501. doi: 10.1016/j.jtcvs.2003.11.047.
The objective of this study was to examine the long-term patient outcomes of lung transplantation in a single center.
Between 1983 and 2003, 521 lung transplants were performed in 501 patients. Major indications were cystic fibrosis (n = 124), chronic obstructive pulmonary disease (n = 88), alpha-1 antitrypsin deficiency (n = 63), pulmonary fibrosis (n = 97), primary pulmonary hypertension (n = 35), Eisenmenger syndrome (n = 21), and miscellaneous end-stage lung diseases (n = 93).
The 5-, 10-, and 15-year survivals for all recipients were 55.1% (95% confidence interval: +/-5%), 35.3% (+/-6%), and 26.5% (+/-11%), respectively. The most common causes of death were sepsis and bronchiolitis obliterans syndrome. Despite an increased postoperative mortality rate, patients with primary pulmonary hypertension achieved the best long-term survival (10-year survival: 59%). Recipients with cystic fibrosis without Burkholderia cepacia infection achieved significantly better long-term survival (10-year survival: 52%) than those with Burkholderia cepacia infection (10-year survival: 15%). The 10-year survival was also significantly better in recipients with chronic obstructive pulmonary disease (43%) than in recipients with alpha-1 antitrypsin deficiency (23%). Although the incidence of bronchiolitis obliterans syndrome was similar between recipients with chronic obstructive pulmonary disease (39%) and alpha-1 antitrypsin deficiency (46%), recipients with alpha-1 antitrypsin deficiency died of sepsis more frequently than recipients with chronic obstructive pulmonary disease (27% vs 6%, respectively; P =.0003).
Although bronchiolitis obliterans syndrome and sepsis still limit the durability of the benefit, lung transplantation returns many patients with end-stage lung disease to active and productive lives. Differences in the complications and long-term survival show the important contribution of the recipient diagnosis to the success of lung transplantation.
本研究的目的是在单一中心研究肺移植患者的长期预后情况。
1983年至2003年间,对501例患者实施了521例肺移植手术。主要适应证包括囊性纤维化(n = 124)、慢性阻塞性肺疾病(n = 88)、α-1抗胰蛋白酶缺乏症(n = 63)、肺纤维化(n = 97)、原发性肺动脉高压(n = 35)、艾森曼格综合征(n = 21)以及其他各种终末期肺病(n = 93)。
所有受者的5年、10年和15年生存率分别为55.1%(95%置信区间:±5%)、35.3%(±6%)和26.5%(±11%)。最常见的死亡原因是脓毒症和闭塞性细支气管炎综合征。尽管术后死亡率有所上升,但原发性肺动脉高压患者的长期生存率最佳(10年生存率:59%)。未感染洋葱伯克霍尔德菌的囊性纤维化受者的长期生存率(10年生存率:52%)显著高于感染洋葱伯克霍尔德菌的受者(10年生存率:15%)。慢性阻塞性肺疾病受者的10年生存率(43%)也显著高于α-1抗胰蛋白酶缺乏症受者(23%)。尽管慢性阻塞性肺疾病受者(39%)和α-1抗胰蛋白酶缺乏症受者(46%)的闭塞性细支气管炎综合征发生率相似,但α-1抗胰蛋白酶缺乏症受者死于脓毒症的频率高于慢性阻塞性肺疾病受者(分别为27%和6%;P = 0.0003)。
尽管闭塞性细支气管炎综合征和脓毒症仍然限制了获益的持久性,但肺移植使许多终末期肺病患者恢复了积极且有意义的生活。并发症和长期生存率的差异表明受者诊断对肺移植成功具有重要影响。